CATEGORIES

22.09.2017

22.09.2017 14:39

Apiax’s $1.5 Million Seed Round Led by Industry Veteran Peter Kurer

Apiax, a RegTech startup transforming complex regulations into easy-to-use digital compliance rules, today announced its Seed Round raise of more than $1.5 Million. The funding was led by Peter Kurer, DIventures, and the Swiss ICT Investor Club (SICTIC) followed by Zürcher Kantonalbank and Tugboat.

22.09.2017 08:10

Tamedia, ZKB und investiere setzen auf Influencer Marketing

Das Zürcher Startup PICSTARS vermarktet die Social Media Reichweite von Sportlern und Eventbesuchern in Zusammenarbeit mit Marken. Mit dem Wachstumskapital der neuen Investoren soll die stark wachsende Plattform zum grössten digitalen Sponsoring-Marktplatz ausgebaut werden.

19.09.2017

19.09.2017 09:38

Biotech start-up TOLREMO closes CHF2,4 million financing round

TOLREMO therapeutics’ aim is to prevent drug resistance in cancer therapy. The successful first financing round allows to advance drug discovery and development efforts. 

15.09.2017

15.09.2017 13:56

Distran secures 7-digit in series A financing round

Zurich based startup Distran, offering ultrasonic inspection solutions, has secured a 7-digit CHF Series A financing. The proceeds will enable Distran to accelerate the market roll-out of its Ultra M, expand its team and operations.

13.09.2017

13.09.2017 08:59

Sophia Genetics raises $30 million

The company will use the resources to further develop its cutting-edge technology. Additionally, the company will continue recruiting top talent and accelerate hospitals’ adoption of clinical genomics testing.

12.09.2017

12.09.2017 10:57

Kenzen: Combining US sales culture with Swiss technology

Kenzen, an innovator of wearables for precision health, has two headquarters in San Francisco and Switzerland. The combination works well, the start-up raised $5 million from strategic investors. The team in Switzerland will now be expanded. 

05.09.2017

05.09.2017 11:45

AMAL Therapeutics raises CHF 8.8 million in Series B round

AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, announces today that it has completed the first tranche of its Series B financing round, raising of Euros 8 million (CHF 8.8 million). AMAL will use the funds to progress its lead vaccine and further develop its proprietary therapeutic tumour vaccination technology platform called KISIMA.

Show All

Events

02.10.2017 17:00 - 20:00

Seif Award ceremony 2017 Volkshaus Zurich, Stauffacherstrasse 60, 8004 Zürich

Show All

Trainings

04.10.2017 @EPFL; 17:15-21:00

Startup Acceleration Workshop No. 1 : The story of your startup EPFL, Route Cantonale 1015 Lausanne BC 01/02

Top viewed

Show All

Video

Tweets

Principal

Partners

Contributors